Studying acalabrutinib with R-CHOP for untreated mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma that has been confirmed by specific lab tests.
- You have not received any previous treatment for your lymphoma.
- You are not able to have a stem cell transplant using your own cells.
- You have tumors that can be measured on scans or an enlarged spleen.
- You are well enough to be up and about (ECOG score 0-2).
- You are willing to use effective birth control if sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This study is looking at how well acalabrutinib works in real-world patients who have mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). If you have one of these types of blood cancer and have not had certain other treatments, you may be able to join.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.